Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects

Ponatinib is a BCR-ABL tyrosine kinase inhibitor (TKI) approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia in patients resistant or intolerant to prior TKIs. In vitro studies suggested that metabolism of ponatinib is partially medi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Narasimhan, Narayana I, Dorer, David J, Niland, Katie, Haluska, Frank, Sonnichsen, Daryl
Materialtyp: Artigo
Språk:Inglês
Publicerad: Blackwell Publishing Ltd 2013
Ämnen:
Original Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3781849/
https://ncbi.nlm.nih.gov/pubmed/23801357
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.109
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk